SavedAdd your journal

Journals / Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi / 2012 / Cilt: 17 - Sayı: 4

Colistin in light of current data

Güncel bilgiler işığında kolistin

İftihar KÖKSAL
Oral ÖNCÜL
VOLKAN KORTEN
Sercan ULUSOY
SERHAT ÜNAL
Pages
156–160
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this manuscript the use of colistin has been discussed in the light of current knowledge.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Colistin is a polypeptid antibiotic and it is used to treat infections caused by multidrug-resistant gram-negative bacteria.
📊
Key Findings & Data:For this reason, the systemic administration of colistin has been abandoned for about 20 years in most areas of the world.
💡
Conclusion & Impact:In this manuscript the use of colistin has been discussed in the light of current knowledge.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Colistin is a polypeptid antibiotic and it is used to treat infections caused by multidrug-resistant gram-negative bacteria. The intravenous use of colistin has been considered to be associated with considerable nephrotoxicity and neurotoxicity. For this reason, the systemic administration of colistin has been abandoned for about 20 years in most areas of the world. The emergence of multidrug-resistant gram-negative bacteria in parallel with the lack of new antibacterial agents led scientists to understand the importance of colistin. In this manuscript the use of colistin has been discussed in the light of current knowledge.

Özet

Kolistin polipeptid yapısında, gram-negatif bakterilere etkili bir antibiyotiktir ve çoğul dirençli gram-negatif bakterilerin neden olduğu infeksiyonların tedavisinde kullanılır. İntravenöz kolistin kullanımının ciddi nefrotoksisite ve nörotoksisiteye neden olduğu kabul edilmiştir. Bu nedenle dünyanın birçok yerinde neredeyse 20 yıldır kolistin uygulaması terk edilmiştir. Çoğul dirençli gram-negatif bakterilerin ortaya çıkması ve yeni antibiyotiklerin geliştirilmemesi nedeniyle kolistin yeniden önem kazanmıştır. Bu yazıda güncel bilgiler ışığında kolistin kullanımı tartışılmıştır.

🔖

Cite This Article

KÖKSAL, İ., ÖNCÜL, O., KORTEN, V., ULUSOY, S., ÜNAL, S. (2012). Colistin in light of current data. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, Cilt: 17 - Sayı: 4, 156–160. https://ajindex.com/articles/201563

References (13)

  1. Shorr AF. Review of studies of the impact on gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 2009;37:1463-9
  2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12
  3. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrugresistant gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601
  4. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanosulphonate against Pseudomonas aeruginosa isolates from patients with cystic fibsosis. Antimicrob Agents Chemother 2001;45:781-5
  5. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther 2007;5:811-21
  6. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, et al. Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010;35:194-9
  7. Levin AS, Barone AA, Penço J, Santos MV, Marinho IS, Arruda EA, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-11
  8. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6
  9. Reed MD, Stern RC, O’Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 2001;41:645
  10. Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemotherapy 2003;52:987-92
  11. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010;54:4503-5
  12. Stein A, Raoult D. Colistin: an antimicrobial for the 21st century? Clin Infect Dis 2002;35:901-2
  13. Michalopoulos AS, Tsiodras S, Rello